SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in Lombardy, Italy.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
10 06 2021
Historique:
received: 19 11 2020
accepted: 17 05 2021
entrez: 11 6 2021
pubmed: 12 6 2021
medline: 29 6 2021
Statut: epublish

Résumé

Lombardy is the Italian region most affected by COVID-19. We tested the presence of plasma anti-SARS-CoV-2 IgG antibodies in 3985 employees across 7 healthcare facilities in areas of Lombardy with different exposure to the SARS-CoV-2 epidemic. Subjects filled a questionnaire to self-report on COVID-19 symptoms, comorbidities, smoking, regular or remote working, and the exposure to COVID-infected individuals. We show that the number of individuals exposed to the virus depended on the geographical location of the facility, ranging between 3 and 43%, consistent with the spatial variation of COVID-19 incidence in Lombardy, and correlated with family interactions. We observed a higher prevalence of females than males positive for IgG, however the level of antibodies was similar, suggesting a comparable magnitude of the anti-spike antibody response. IgG positivity among smokers was lower (7.4% vs 13.5%) although without difference in IgG plasma levels. We observed 11.9% of IgG positive asymptomatic individuals and another 23.1% with one or two symptoms. Interestingly, among the IgG positive population, 81.2% of subjects with anosmia/dysgeusia and fever were SARS-CoV-2 infected, indicating that these symptoms are strongly associated to COVID-19. In conclusion, the frequency of IgG positivity and SARS-CoV-2 infection is dependent on the geographical exposure to the virus and primarily to family rather than hospital exposure.

Identifiants

pubmed: 34112899
doi: 10.1038/s41598-021-91773-4
pii: 10.1038/s41598-021-91773-4
pmc: PMC8192543
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

12312

Subventions

Organisme : Italian Ministry of Health
ID : Ricerca corrente

Références

ERJ Open Res. 2020 Jul 13;6(2):
pubmed: 32685435
Vaccines (Basel). 2020 Aug 23;8(3):
pubmed: 32842505
JAMA. 2020 Jun 16;323(23):2425-2427
pubmed: 32421144
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
JAMA. 2020 Jun 9;323(22):2340-2341
pubmed: 32401274
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Eur Respir J. 2020 Aug 27;56(2):
pubmed: 32430429
Nat Rev Immunol. 2020 Jun;20(6):375-388
pubmed: 32132681
Int J Infect Dis. 2020 Sep;98:287-289
pubmed: 32634587
Clin Infect Dis. 2020 Nov 5;71(8):1930-1934
pubmed: 32306047
J Clin Invest. 2020 Nov 2;130(11):6141-6150
pubmed: 32764200
Intern Emerg Med. 2020 Aug;15(5):845-852
pubmed: 32385628
Radiology. 2020 Aug;296(2):E32-E40
pubmed: 32101510
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32580948
Radiology. 2020 Aug;296(2):E41-E45
pubmed: 32049601
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Clin Chem Lab Med. 2020 Jun 25;58(7):1070-1076
pubmed: 32172228
J Hepatol. 2020 Nov;73(5):1063-1071
pubmed: 32526252
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
J Med Virol. 2020 Jul;92(7):903-908
pubmed: 32219885
Elife. 2020 May 11;9:
pubmed: 32392129
EClinicalMedicine. 2021 Mar;33:100770
pubmed: 33718853
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330
Nature. 2020 Aug;584(7821):425-429
pubmed: 32604404
Front Public Health. 2020 Apr 29;8:152
pubmed: 32411652
Vaccines (Basel). 2020 Sep 16;8(3):
pubmed: 32947988

Auteurs

Maria Teresa Sandri (MT)

IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Elena Azzolini (E)

IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Valter Torri (V)

Istituto Di Ricerche Farmacologiche, Mario Negri" - IRCCS, Milan, Italy.

Sara Carloni (S)

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Chiara Pozzi (C)

IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Michela Salvatici (M)

IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Michele Tedeschi (M)

IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Massimo Castoldi (M)

Humanitas Gavazzeni and Castelli, Bergamo, Italy.

Alberto Mantovani (A)

IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
The William Harvey Research Institute, Queen Mary University of London, London, UK.

Maria Rescigno (M)

IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. maria.rescigno@hunimed.eu.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. maria.rescigno@hunimed.eu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH